F11 and infective endocarditis: Emerging FXI inhibitors such as MK-2060 and asundexian are under clinical evaluation across cardiovascular and thromboembolic indications, underscoring the translational potential of combined NETosis and FXI inhibition to modulate immunothrombosis in infective endocarditis [125].